Related Experiment Video

Updated: Mar 25, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

12.3K

Immunosenescence in patients with chronic systolic heart failure

Sotirios Xydonas1, John Parissis, Louiza Lioni

  • 1aSecond Department of Cardiology bDepartment of Immunology-Histocompatibility, Evaggelismos General Hospital cHeart Failure Unit, Department of Cardiology, National and Kapodistrian University of Athens, Attikon General Hospital, Athens University dMicrobiology Department, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Journal of Cardiovascular Medicine (Hagerstown, Md.)
|February 25, 2016
PubMed

Insights

Chronic heart failure patients show signs of immunosenescence, an aging immune system. Advanced stages correlate with T-cell aging, suggesting increased risk for adverse events in these heart failure patients.

Area of Science:

  • Immunology
  • Cardiology
  • Gerontology

Background:

  • Chronic heart failure (CHF) involves immune system activation.
  • Immunosenescence, or immune system aging, is a hallmark of aging and disease.
  • The relationship between immunosenescence and CHF stages is not well understood.

Purpose of the Study:

  • To investigate the presence and severity of immunosenescence in patients with CHF.
  • To determine the association between immunosenescence and the stages of CHF.

Main Methods:

  • 86 stable systolic CHF patients were enrolled.
  • Flow cytometry was used to analyze leukocyte and lymphocyte subpopulations.
  • Functional status was assessed using the New York Heart Association (NYHA) classification.

Main Results:

  • Advanced CHF patients had increased neutrophils and decreased lymphocytes.
  • T-helper cells increased, while B-cells and T cytotoxic cells decreased.
  • T-helper cells showed significant differentiation and aging across NYHA classes, with reduced naïve and increased memory T-cells in NYHA Class IV.

Conclusions:

  • CHF patients exhibit significant T-cell differentiation and aging.
  • Immunosenescence is present in advanced CHF.
  • This immunosenescence may indicate a higher risk for adverse events in CHF patients.
Abstract

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.5K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
512
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
830
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
537